LAMIVUDINE
Generic: LAMIVUDINE ORAL
Chartwell RXManufacturer
ORALRoute
LAMIVUDINEActive Substance
2014-10-31Original Approval
LAMIVUDINE is FDA application ANDA203564, sponsored by CHARTWELL MOLECULAR. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Top Reported Reactions
1
FOETAL EXPOSURE DURING PREGNANCY
1,983 reports
2
VIROLOGIC FAILURE
1,971 reports
3
DRUG RESISTANCE
1,913 reports
4
DRUG INTERACTION
1,817 reports
5
PATHOGEN RESISTANCE
1,806 reports
6
VIRAL MUTATION IDENTIFIED
1,711 reports
7
DRUG INEFFECTIVE
1,109 reports
8
DEPRESSION
1,073 reports
9
TREATMENT FAILURE
1,041 reports
10
PYREXIA
994 reports